Department of Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia.
College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi Arabia.
J Oncol Pharm Pract. 2023 Jan;29(1):183-190. doi: 10.1177/10781552221110806. Epub 2022 Jul 3.
Patients with refractory/early relapsed aggressive lymphomas belong to the most difficult-to-treat patients with hematological neoplasia. The prognosis of such patients is poor and novel treatment approches are urgently needed. Autologous chimeric antigen receptor T-cell therapy is a promising new therapy option that is approved after the failure of two lines of chemotherapy. Recently, the results of three different CART studies (ZUMA-7, TRANSFORM, and BELINDA) were published. Two of them were positive and one was negative, which created a mix of disappointment, confusion, and irritation. In this article, we are analyzing the data of all three trials and shed light on the differences between the studies which may facilitate an easier understanding of the results and relevance of CART in aggressive large B-cell lymphoma.
难治/早期复发侵袭性淋巴瘤患者属于血液系统恶性肿瘤中最难治疗的患者之一。此类患者的预后较差，迫切需要新的治疗方法。自体嵌合抗原受体 T 细胞疗法是一种有前途的新治疗选择，在二线化疗失败后获得批准。最近，三项不同的 CART 研究（ZUMA-7、TRANSFORM 和 BELINDA）的结果公布。其中两项为阳性，一项为阴性，这让人感到失望、困惑和恼怒。在本文中，我们分析了所有三项试验的数据，并阐明了研究之间的差异，这可能有助于更轻松地理解 CART 在侵袭性大 B 细胞淋巴瘤中的结果和相关性。
